2’-O-MOE-U-3’-phosphoramidite
This product is a uridine nucleoside building block featuring a 2’-O-methoxyethyl (MOE) modification and a 3’-phosphoramidite group for automated solid-phase oligonucleotide synthesis. The MOE modification enhances nuclease resistance, binding affinity, and pharmacokinetic properties, making it especially used in antisense oligonucleotide (ASO) and RNA therapeutic development.
Key Features and Benefits:
-
2’-O-MOE Modification: Improves nuclease stability and enhances RNA binding affinity.
-
Uridine Base: Preserves native pyrimidine pairing for biological compatibility.
-
3’-Phosphoramidite: Compatible with automated DNA/RNA synthesis workflows.
-
High Purity: HPLC-purified, suitable for therapeutic oligonucleotide synthesis.
-
Enhanced Pharmacokinetics: Supports improved in vivo half-life and efficacy.
Applications:
-
Antisense Oligonucleotides (ASOs): Widely used for therapeutic oligo design.
-
siRNA and RNA Therapeutics: Improves stability and target engagement.
-
Oligonucleotide Research: For structure–activity relationship studies.
-
Drug Development: Essential in designing stable, next-generation oligonucleotide drugs.
Storage and Handling:
-
Storage: Store dry at –20 °C under inert atmosphere.
-
Handling: Use anhydrous acetonitrile and standard phosphoramidite synthesis protocols.
This product provides the stability and enhanced performance specifically required for advanced oligonucleotide therapeutics and research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
